Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters

Database
Language
Affiliation country
Publication year range
1.
Mol Neurobiol ; 54(6): 3935-3947, 2017 08.
Article in English | MEDLINE | ID: mdl-27246566

ABSTRACT

Studies have shown that changes in energy metabolism are involved in the pathophysiology of bipolar disorder (BD). It was suggested that omega-3 (ω3) fatty acids have beneficial properties in the central nervous system and that this fatty acid plays an important role in energy metabolism. Therefore, the study aimed to evaluate the effect of ω3 fatty acids alone and in combination with lithium (Li) or valproate (VPA) on behaviour and parameters of energy metabolism in an animal model of mania induced by fenproporex. Our results showed that co-administration of ω3 fatty acids and Li was able to prevent and reverse the increase in locomotor and exploratory activity induced by fenproporex. The combination of ω3 fatty acids with VPA was only able to prevent the fenproporex-induced hyperactivity. For the energy metabolism parameters, our results showed that the administration of Fen for the reversal or prevention protocol inhibited the activities of succinate dehydrogenase, complex II and complex IV in the hippocampus. However, hippocampal creatine kinase (CK) activity was decreased only for the reversal protocol. The ω3 fatty acids, alone and in combination with VPA or Li, prevented and reversed the decrease in complex II, IV and succinate dehydrogenase activity, whereas the decrease in CK activity was only reversed after the co-administration of ω3 fatty acids and VPA. In conclusion, our results showed that the ω3 fatty acids combined with VPA or Li were able to prevent and reverse manic-like hyperactivity and the inhibition of energy metabolism in the hippocampus, suggesting that ω3 fatty acids may play an important role in the modulation of behavioural parameters and energy metabolism.


Subject(s)
Antimanic Agents/therapeutic use , Behavior, Animal , Bipolar Disorder/drug therapy , Bipolar Disorder/metabolism , Energy Metabolism/drug effects , Fatty Acids, Omega-3/therapeutic use , Amphetamines , Animals , Antimanic Agents/pharmacology , Bipolar Disorder/chemically induced , Bipolar Disorder/genetics , Citrate (si)-Synthase/metabolism , Creatine Kinase/metabolism , Disease Models, Animal , Fatty Acids, Omega-3/administration & dosage , Fatty Acids, Omega-3/pharmacology , Gene Expression Regulation/drug effects , Lithium/administration & dosage , Lithium/pharmacology , Lithium/therapeutic use , Male , Rats, Wistar , Succinate Dehydrogenase/metabolism , Valproic Acid/administration & dosage , Valproic Acid/pharmacology , Valproic Acid/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL